Sertraline Interactions

Sertraline is an SSRI that blocks serotonin reuptake, and St. John's wort independently inhibits serotonin reuptake and contains constituents (hyperforin, hypericin) that elevate central serotonin. Combining them can trigger serotonin syndrome, a potentially life-threatening syndrome of altered mental status, autonomic instability, and neuromuscular hyperactivity. St. John's wort also induces CYP3A4 and CYP2C19, which can lower sertraline plasma levels and undermine treatment.

Sertraline blocks serotonin reuptake and 5-HTP (5-hydroxytryptophan) is the immediate biochemical precursor of serotonin, so it directly increases serotonin synthesis. Combining the two stacks production and reuptake blockade, which can precipitate serotonin syndrome.

SAM-e (S-adenosyl-L-methionine) has its own antidepressant and serotonergic effects, and combining it with the SSRI sertraline can additively raise serotonergic activity and increase the risk of serotonin syndrome. Case reports describe mania and serotonin-toxicity-like presentations in patients combining SAM-e with SSRIs.

Kava (Piper methysticum) has central nervous system depressant effects and a documented risk of hepatotoxicity, and combining it with sertraline raises the risk of additive sedation and liver injury. Sertraline itself is associated with hepatic adverse effects in a small subset of users, and stacking hepatotoxic agents is discouraged.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin, and L-tryptophan is the dietary precursor to serotonin. Combining them can excessively elevate serotonergic activity, raising the risk of serotonin syndrome (agitation, tremor, hyperthermia, autonomic instability).

Sertraline (Zoloft) and alcohol are both central nervous system depressants. Although controlled studies in healthy subjects showed sertraline did not potentiate alcohol's psychomotor impairment, the FDA label still advises against concurrent use because alcohol can worsen depression, anxiety, drowsiness, and judgment in patients being treated for mood disorders.

CBD inhibits CYP2C19, an enzyme that contributes to sertraline metabolism. A published case report describes severe hyponatremia and cognitive dysfunction in a CYP2C19 intermediate metabolizer who added over-the-counter CBD to chronic sertraline, consistent with phenoconversion to a poor-metabolizer phenotype.

Sertraline modestly inhibits CYP1A2-mediated caffeine metabolism, raising caffeine plasma levels and prolonging its half-life. Caffeine can also worsen the anxiety, insomnia, jitteriness, and palpitations that sertraline is often prescribed to treat, blunting the clinical response.

Sertraline and caffeine can each contribute to anxiety, insomnia, tremor and GI upset, and sertraline may modestly slow caffeine clearance via CYP1A2 inhibition. The pharmacokinetic effect is small but the additive symptomatic effect can be uncomfortable.